EyePoint Pharmaceuticals (EYPT) Stock Forecast & Price Target

Compare

1,000 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EYPT Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

EyePoint

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EYPT Stock 12 Month Forecast

Average Price Target

$36.60

▲(177.27% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for EyePoint Pharmaceuticals in the last 3 months. The average price target is $36.60 with a high forecast of $68.00 and a low forecast of $20.00. The average price target represents a 177.27% change from the last price of $13.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","69":"$69","20.25":"$20.3","36.5":"$36.5","52.75":"$52.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$68.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$36.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,20.25,36.5,52.75,69],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.34,22.16,25.98,29.799999999999997,33.62,37.44,41.26,45.08,48.9,52.72,56.53999999999999,60.36,64.17999999999999,{"y":68,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.34,19.744615384615386,21.14923076923077,22.553846153846155,23.95846153846154,25.363076923076925,26.767692307692307,28.172307692307694,29.57692307692308,30.981538461538463,32.386153846153846,33.79076923076923,35.19538461538462,{"y":36.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.34,18.467692307692307,18.595384615384614,18.723076923076924,18.85076923076923,18.978461538461538,19.106153846153845,19.233846153846155,19.361538461538462,19.48923076923077,19.616923076923076,19.744615384615386,19.872307692307693,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.27,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.13,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.42,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.73,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.915,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.09,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.26,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.27,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.29,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.34,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$68.00

Average Price Target$36.60

Lowest Price Target$20.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Graig Suvannavejh

Mizuho Securities

$36

Buy

172.73%

Upside

Reiterated

03/11/26

EyePoint Pharmaceuticals (EYPT) Receives a Buy from Mizuho Securities

Tessa Romero

J.P. Morgan

$33

Buy

150.00%

Upside

Reiterated

03/10/26

J.P. Morgan Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)

Tara Bancroft

TD Cowen

$20

Buy

51.52%

Upside

Reiterated

03/09/26

EyePoint Pharmaceuticals: Strong Clinical Momentum, Favorable Risk‑Reward, and Catalyst‑Rich Path to Duravyu Approval Support Buy Rating

Yigal Nochomovitz

Citi

$31→$35

Buy

165.15%

Upside

Reiterated

03/09/26

EyePoint price target raised to $35 from $31 at CitiEyePoint price target raised to $35 from $31 at Citi

Debanjana Chatterjee

JonesTrading

$43

Buy

225.76%

Upside

Reiterated

03/06/26

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT), Omada Health, Inc. (NASDAQ: OMDA) and BridgeBio Oncology Therapeutics (NASDAQ: BBOT)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$33

Buy

150.00%

Upside

Reiterated

03/05/26

EyePoint Pharmaceuticals (EYPT) Receives a Buy from Jefferies

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$18→$68

Buy

415.15%

Upside

Reiterated

03/05/26

Guggenheim Remains a Buy on EyePoint Pharmaceuticals (EYPT)

Yi Chen

H.C. Wainwright

$23→$30

Buy

127.27%

Upside

Reiterated

03/05/26

EyePoint price target raised to $30 from $23 at H.C. WainwrightEyePoint price target raised to $30 from $23 at H.C. Wainwright

Daniil Gataulin

Chardan Capital

$27→$29

Buy

119.70%

Upside

Assigned

03/04/26

EyePoint price target raised to $29 from $27 at ChardanEyePoint price target raised to $29 from $27 at Chardan

Lisa Walter

RBC Capital

$39

Buy

195.45%

Upside

Reiterated

03/04/26

EyePoint Pharmaceuticals (EYPT) Gets a Buy from RBC Capital

Greg Harrison

Scotiabank

$18

Buy

36.36%

Upside

Reiterated

08/07/25

Scotiabank Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Graig Suvannavejh

Mizuho Securities

$36

Buy

172.73%

Upside

Reiterated

03/11/26

EyePoint Pharmaceuticals (EYPT) Receives a Buy from Mizuho Securities

Tessa Romero

J.P. Morgan

$33

Buy

150.00%

Upside

Reiterated

03/10/26

J.P. Morgan Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)

Tara Bancroft

TD Cowen

$20

Buy

51.52%

Upside

Reiterated

03/09/26

EyePoint Pharmaceuticals: Strong Clinical Momentum, Favorable Risk‑Reward, and Catalyst‑Rich Path to Duravyu Approval Support Buy Rating

Yigal Nochomovitz

Citi

$31→$35

Buy

165.15%

Upside

Reiterated

03/09/26

EyePoint price target raised to $35 from $31 at CitiEyePoint price target raised to $35 from $31 at Citi

Debanjana Chatterjee

JonesTrading

$43

Buy

225.76%

Upside

Reiterated

03/06/26

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (NASDAQ: EYPT), Omada Health, Inc. (NASDAQ: OMDA) and BridgeBio Oncology Therapeutics (NASDAQ: BBOT)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$33

Buy

150.00%

Upside

Reiterated

03/05/26

EyePoint Pharmaceuticals (EYPT) Receives a Buy from Jefferies

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$18→$68

Buy

415.15%

Upside

Reiterated

03/05/26

Guggenheim Remains a Buy on EyePoint Pharmaceuticals (EYPT)

Yi Chen

H.C. Wainwright

$23→$30

Buy

127.27%

Upside

Reiterated

03/05/26

EyePoint price target raised to $30 from $23 at H.C. WainwrightEyePoint price target raised to $30 from $23 at H.C. Wainwright

Daniil Gataulin

Chardan Capital

$27→$29

Buy

119.70%

Upside

Assigned

03/04/26

EyePoint price target raised to $29 from $27 at ChardanEyePoint price target raised to $29 from $27 at Chardan

Lisa Walter

RBC Capital

$39

Buy

195.45%

Upside

Reiterated

03/04/26

EyePoint Pharmaceuticals (EYPT) Gets a Buy from RBC Capital

Greg Harrison

Scotiabank

$18

Buy

36.36%

Upside

Reiterated

08/07/25

Scotiabank Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering EyePoint Pharmaceuticals

3 Months

xxx

Success Rate

11/21 ratings generated profit

Average Return

+13.85%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.38% of your transactions generating a profit, with an average return of +13.85% per trade.

1 Year

Debanjana ChatterjeeJonesTrading

Success Rate

9/14 ratings generated profit

Average Return

+37.60%

Copying Debanjana Chatterjee's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +37.60% per trade.

2 Years

xxx

Success Rate

10/14 ratings generated profit

Average Return

+32.27%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +32.27% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EYPT Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EYPT has received 21 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. EYPT average Analyst price target in the past 3 months is 36.60.

Each month's total comprises the sum of three months' worth of ratings.

EYPT Financial Forecast

EYPT Earnings Forecast

Next quarter’s earnings estimate for EYPT is -$0.82 with a range of -$0.91 to -$0.76. The previous quarter’s EPS was -$0.81. EYPT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year EYPT has Performed in-line its overall industry.

EYPT Sales Forecast

Next quarter’s sales forecast for EYPT is $978.00K with a range of $0.00 to $8.10M. The previous quarter’s sales results were $620.00K. EYPT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year EYPT has Performed in-line its overall industry.

EYPT Stock Forecast FAQ

What is EYPT’s average 12-month price target, according to analysts?

Based on analyst ratings, EyePoint Pharmaceuticals Inc’s 12-month average price target is 36.60.

What is EYPT’s upside potential, based on the analysts’ average price target?

EyePoint Pharmaceuticals Inc has 177.27% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EYPT a Buy, Sell or Hold?

EyePoint Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is EyePoint Pharmaceuticals Inc’s price target?

The average price target for EyePoint Pharmaceuticals Inc is 36.60. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $68.00 ,the lowest forecast is $20.00. The average price target represents 177.27% Increase from the current price of $13.2.

What do analysts say about EyePoint Pharmaceuticals Inc?

EyePoint Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of EYPT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

EyePoint Pharmaceuticals (EYPT) Stock Forecast & Price Target

EYPT Analyst Ratings

EYPT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering EyePoint Pharmaceuticals

EYPT Analyst Recommendation Trends

EYPT Financial Forecast

EYPT Earnings Forecast

EYPT Sales Forecast

EYPT Stock Forecast FAQ

Detailed List of Analyst Forecasts